drugset
drugset / Trial / NCT00265863

Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

NCT00265863 ↗

Phase 2 Terminated 1 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients with malignant ascites.

Timeline

Start
2004-08
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified — Other

Indications

metastatic malignant neoplasm